S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65

Ceapro Stock Forecast, Price & News

+0.01 (+1.64 %)
(As of 10/18/2021 03:48 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume52,003 shs
Average Volume42,110 shs
Market CapitalizationC$48.16 million
P/E Ratio88.57
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CZO News and Ratings via Email

Sign-up to receive the latest news and ratings for Ceapro and its competitors with MarketBeat's FREE daily newsletter.

About Ceapro

Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19; and a research project with the University of Alberta to expand the utilization of the PGX technology and generate ingredients targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
C$15.29 million
Cash Flow
C$0.09 per share
Book Value
C$0.33 per share





Market Cap
C$48.16 million
Next Earnings Date
11/26/2021 (Estimated)
Not Optionable


Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Ceapro (CVE:CZO) Frequently Asked Questions

What stocks does MarketBeat like better than Ceapro?

Wall Street analysts have given Ceapro a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ceapro wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ceapro's next earnings date?

Ceapro is scheduled to release its next quarterly earnings announcement on Friday, November 26th 2021.
View our earnings forecast for Ceapro

How has Ceapro's stock been impacted by COVID-19 (Coronavirus)?

Ceapro's stock was trading at C$0.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CZO stock has increased by 181.8% and is now trading at C$0.62.
View which stocks have been most impacted by COVID-19

Who are Ceapro's key executives?

Ceapro's management team includes the following people:
  • Mr. Gilles R. Gagnon M.B.A., M.Sc., MBA, ICD.D, CEO, Pres & Director (Age 67, Pay $480k)
  • Ms. Stacy Prefontaine CPA, CA, CFO & Corp. Sec.
  • Dr. Bernhard Seifried, Sr. Director of Research & Technology

What other stocks do shareholders of Ceapro own?

What is Ceapro's stock symbol?

Ceapro trades on the Canadian Venture Exchange (CVE) under the ticker symbol "CZO."

How do I buy shares of Ceapro?

Shares of CZO and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Ceapro's stock price today?

One share of CZO stock can currently be purchased for approximately C$0.62.

How much money does Ceapro make?

Ceapro has a market capitalization of C$48.16 million and generates C$15.29 million in revenue each year.

What is Ceapro's official website?

The official website for Ceapro is www.ceapro.com.

Where are Ceapro's headquarters?

Ceapro is headquartered at 7824 51 Ave NW, EDMONTON, AB T6E 6W2, Canada.

How can I contact Ceapro?

Ceapro's mailing address is 7824 51 Ave NW, EDMONTON, AB T6E 6W2, Canada. The company can be reached via phone at +1-780-4214555.

This page was last updated on 10/19/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.